Otsuka's tolvaptan meets in Phase III for ADKPD

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) reported data from the Phase III REPRISE trial in 1,370 patients with autosomal dominant polycystic kidney disease

Read the full 234 word article

User Sign In